Loading stock…

PTC Therapeutics, Inc. (PTCT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

PTC Therapeutics, Inc.

PTCTMarket cap $5.28BPrice $63.2

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for rare genetic disorders, including Duchenne muscular dystrophy and neurometabolic diseases, targeting patients most drugmakers ignore. Its RNA-based therapies read through genetic errors, turning "undruggable" mutations into viable treatment targets for diseases affecting just thousands worldwide.

In Bastion Portfolios?

52W Return-4%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+35%10

Revenue Forecast

Rev CAGR (1y)-26%1

Rev CAGR (3y)-3%1

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+1-77%1

EPS Growth Y+2+53%9

EPS Growth Y+3+27%8

Quality

Margins

EBIT Margin11%5

Net Income Margin-4%2

Free Cash Flow Margin-4%2

Debt

Net Debt/EBITDA4.12

Efficiency

ROEna–

ROA-1%2

Earnings Stability22

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)382

P/E Ratio (Forward 3y)164

P/BVna–

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd175

Yield

Free Cash Flow Yield-0.8%2

Dividend Yieldna–

Momentum

Short term

1 month return-8%3

3 month return-29%1

YTD return-17%3

Mid term

Price vs 52wHigh70%3

1 year return-2%4

Long term

3 year return+193%9

5 year return+72%7

Risk Shield

Price Risk

Beta1.04

Volatility40%4

Free Cash Flow

Free Cash Flow Margin-4%2

Free Cash Flow Yield-0.8%2

Quality

ROCE5%3

Earnings Stability22

Net Debt/EBITDA4.12

02Growth

Is it actually growing, and how fast?

PTCTPTC Therapeutics

Revenue FY25$1.7B

GROWTH RATING↗

VERY WEAK14 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+35%10

Revenue, next 1Y-26%1

Revenue, next 3Y, CAGR-3%1

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-77%1

EPS growth, FY27E+53%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 35%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 86% of companies worldwide.

Revenue is set to shrink 3%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 35%/yr over the last 3 years, but it is set to shrink 3%/yr from here.

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-29%1

YTD return-17%3

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-2%4

3-year return+193%9

5-year return+72%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +193% over three years and +72% over five, ahead of 70% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 2% over the past year, now 30% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-8%), over three months (-29%) and so far this year (-17%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on PTC Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PTCTPTC Therapeutics

Revenue FY25$1.7B

GROWTH RATING↗

VERY WEAK14 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+35%10

Revenue, next 1Y-26%1

Revenue, next 3Y, CAGR-3%1

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-77%1

EPS growth, FY27E+53%9

EPS growth, FY28E+27%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 35%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 86% of companies worldwide.

Revenue is set to shrink 3%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 35%/yr over the last 3 years, but it is set to shrink 3%/yr from here.

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-29%1

YTD return-17%3

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-2%4

3-year return+193%9

5-year return+72%7

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +193% over three years and +72% over five, ahead of 70% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 2% over the past year, now 30% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-8%), over three months (-29%) and so far this year (-17%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on PTC Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community